The AMR Action Fund aims to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline.
The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics
Strengthens and accelerates the research and development of antibiotics through investment and provision of industry resources and expertise to biotechnology companies.
Brings together a broad alliance of industry and non-industry stakeholders, including philanthropies, development banks, and multilaterals, to encourage governments to create market conditions that enable sustainable investment in the pipeline.
Created by leading pharmaceutical companies
Supported by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
Management
Henry Skinner
CEOOur CEO, Dr. Henry Skinner joins the Fund from Tekla Capital Management, where he was Senior Vice President, Venture. Prior to joining Tekla, Dr. Skinner Served as Deputy Head and Managing Director of Novartis Venture Fund. In addition, Dr. Skinner has been CEO of SelectX Pharmaceuticals and NeoGenesis Pharmaceuticals and has held positions in Business Development for Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn and Lexicon Genetics. Dr. Skinner was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois and M.S. and B.S. in Biology/Biotechnology from Worcester Polytechnic Institute.
Martin Bott
CEO (Interim)Martin Bott, our interim CEO, is Vice-President Finance at Eli Lilly and Company, responsible for special projects.
During his 31 year career at Lilly, Martin has held a series of leadership roles with growing responsibilities mainly in finance, business development, and project management. Notably, he has served as the CFO of Lilly Diabetes, CFO of Global Manufacturing, led the Corporate Finance and Investment Banking group, and recently led the strategic review and resulting IPO and spin off of Lilly’s animal health division – Elanco Animal Health. Martin has lived and worked in the US, Germany, UK, and Switzerland.
He holds a Master’s Degree of International Business from the University of South Carolina and a Commercial Assistant degree from Bayer AG/Chamber of Commerce Cologne.
Silas Holland
Head of External Affairs (Interim)Silas Holland, our interim Head of External Affairs, is a Director for Global Public Policy at MSD, where he is responsible for global health policy issues related to infectious disease.
Over the past 15 years, he has worked on programs at both the community- and global-level to expand access to medicines. He joined MSD in 2016 from the Global Fund to Fight AIDS, Tuberculosis, and Malaria, where he was responsible for the sourcing of tuberculosis health products. He has also worked for the World Health Organization and Stop TB Partnership in Geneva.
He earned a BA in Biology from Duke University and has postgraduate degrees in education (Loyola Marymount University) and public health (University of Pretoria).
Ted Murphy
Head of Operations (Interim)Ted Murphy, our interim Director of Operations, was formerly a Finance Director at Eli Lilly and Company, responsible for special projects.
Over a nearly 10-year career, Ted has worked in a variety of different roles across finance, operations, and entrepreneurship. His career at Lilly began in the finance function with roles of increasing responsibility across Manufacturing, R&D, and Treasury. Most recently, he transitioned into the operations group supporting the Immunology portfolio. He was the co-founder of Theia Medical, a medical device startup and served as an advisor to numerous early stage companies across the US and in Europe.
Ted holds a Master’s in Business Administration from Stanford Graduate School of Business and a Bachelor of Science in Economics from Purdue University.